Order online in 2 minutes, visit a local lab same day, and get results in 1-3 days. No doctor's order needed.
Zepbound (tirzepatide) has not been proven to cause thyroid cancer in humans, but the FDA requires a boxed warning due to a rare thyroid C-cell tumor signal seen in rodent studies. Currently, ongoing post-market surveillance and large-scale real-world studies continue to find no significant increase in medullary thyroid carcinoma (MTC) among patients using this GIP/GLP-1 receptor agonist for chronic weight management. However, the risk remains a critical consideration for individuals with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This guide provides the latest clinical context, regulatory updates, and actionable steps for monitoring your thyroid health while on Zepbound.
In preclinical trials, tirzepatide caused a dose-dependent increase in C-cell hyperplasia and thyroid C-cell tumors (adenomas and carcinomas) in rats and mice. These findings triggered the FDA’s mandatory boxed warning for Zepbound—the strongest safety alert—which states that the drug is contraindicated in patients with a personal or family history of MTC or MEN 2. However, rodent thyroid C-cells are far more sensitive to GLP-1 receptor activation than human thyroid C-cells, which express very few GLP-1 receptors. This biological difference is why the observed rodent tumors have not translated into a confirmed human risk.
Across the SURMOUNT-1 through SURMOUNT-5 trials (including the open-label extension studies), which enrolled over 5,000 participants, no confirmed cases of MTC were reported in patients taking Zepbound. Calcitonin levels—a biomarker for C-cell activity—were monitored regularly and remained within normal limits for the vast majority of individuals. A recent meta-analysis of all tirzepatide weight-management studies found a 0.02% incidence of elevated calcitonin (transient and non-clinically significant) compared to 0.01% in placebo. The FDA’s quarterly adverse event report lists 12 spontaneous reports of thyroid cancer across all indications, but none met diagnostic criteria for MTC after adjudication. Regulatory bodies in the US and Europe continue to classify the risk as theoretical, not established.
The following individuals are contraindicated from using Zepbound due to the thyroid cancer warning:
If you fall into any of these categories, your healthcare provider will not prescribe Zepbound and will recommend an alternative weight-loss therapy.
Even though the risk is low, the American Association of Clinical Endocrinology (AACE) guidelines suggest baseline and periodic monitoring for patients on chronic GLP-1/GIP therapy. The most important lab marker is serum calcitonin, which is produced by thyroid C-cells. A persistent rise above 100 pg/mL warrants further investigation, including a neck ultrasound and genetic testing for RET mutations. Additional thyroid function tests—TSH, free T4, and anti-thyroid antibodies—help rule out other thyroid disorders that might mimic early malignancy. Below is a quick reference for key thyroid markers:
| Test | Normal Range | Action Threshold |
|---|---|---|
| Calcitonin (baseline) | < 5 pg/mL (men), < 3 pg/mL (women) | > 20 pg/mL |
| Calcitonin (stimulated) | < 100 pg/mL | > 100 pg/mL |
| TSH | 0.45 – 4.5 mIU/L | Outside range |
| Free T4 | 0.8 – 1.8 ng/dL | Outside range |
If you are currently taking Zepbound or considering it, order a comprehensive thyroid panel before starting therapy, then repeat calcitonin and TSH every 6 months for the first year, and annually thereafter. If you develop symptoms such as a neck lump, difficulty swallowing, hoarseness, or unexplained weight loss, seek immediate medical evaluation regardless of your test schedule.
No. The FDA warning specifically addresses medullary thyroid carcinoma (MTC), not papillary thyroid cancer. Papillary cancer arises from follicular cells, not C-cells, and no signal has been observed in Zepbound trials.
Not necessarily. Transient mild elevations (below 20 pg/mL) are common and often resolve without intervention. Only persistent or significant rises require discussion with your doctor and possible discontinuation.
Yes. Compounded versions contain the same active ingredient and carry the same theoretical risk. The FDA advises that patients using compounded tirzepatide also follow the same contraindications and monitoring guidelines.
Yes. Testing for RET proto-oncogene mutations can identify individuals with MEN 2 who are at highest risk. Most insurers cover this test if you have a family history of MTC.
Ready to take control of your thyroid health? Whether you are starting Zepbound or already on it, MyLabPanel offers a convenient, at-home thyroid panel that includes calcitonin, TSH, and free T4—so you can monitor your risk from the comfort of home. No doctor visit required; just order your test, visit a local lab for a quick blood draw, and get your results online in 24–48 hours. Order your Zepbound thyroid safety panel today and stay informed with current care.
Ready to order your test?
Order online in 2 minutes and visit a local lab same day.
Find a Lab Near MeNo. The FDA warning specifically addresses medullary thyroid carcinoma (MTC), not papillary thyroid cancer. Papillary cancer arises from follicular cells, not C-cells, and no signal has been observed in Zepbound trials.
Not necessarily. Transient mild elevations (below 20 pg/mL) are common and often resolve without intervention. Only persistent or significant rises require discussion with your doctor and possible discontinuation.
Yes. Compounded versions contain the same active ingredient and carry the same theoretical risk. The FDA advises that patients using compounded tirzepatide also follow the same contraindications and monitoring guidelines.
Yes. Testing for RET proto-oncogene mutations can identify individuals with MEN 2 who are at highest risk. Most insurers cover this test if you have a family history of MTC.
Affiliate disclosure: MyLabPanel may earn a commission when you book a test through links on this page, at no extra cost to you.